Ximelagatran is effective alternative to warfarin

摘要

A new oral anti-clotting drug, ximelaga-tran (Exanta), is an effective alternative to warfarin for preventing stroke in patients with atrial fibrillation, researchers say.A fixed dose of ximelagatran (36mg twice a day) was compared with dose-adjusted warfarin in preventing stroke and systemic embolic events in 3,922 people with atrial fibrillation and at least one additional risk factor for stroke in a study called SPORTIF V. Patients were treated for an average of 20 months.